Literature DB >> 32524458

Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study.

Job P van Kooten1, Arvind Oemrawsingh1, Nadine L de Boer1, Cornelis Verhoef1, Jacobus W A Burger1,2, Eva V E Madsen1, Alexandra R M Brandt-Kerkhof3.   

Abstract

BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for peritoneal carcinomatosis.
OBJECTIVE: The aim of this study was to determine the predictive value of postoperative inflammatory biomarkers in assessing complications after CRS and HIPEC.
METHODS: A prospective database of 181 patients, who underwent CRS-HIPEC between March 2014 through April 2018 in the Erasmus MC, was retrospectively analyzed. Postoperative complications were defined according to the serious adverse event (SAE) grading system. Levels of C-reactive protein (CRP) and white blood cell (WBC) count were compared between patients with SAE grade < 3 and SAE grade ≥ 3. The area under the receiver operating characteristic curve (AUC) was calculated for CRP and WBC against SAE ≥ 3 and various intra-abdominal complications.
RESULTS: SAE ≥ 3 postoperative complications occurred in 50 patients. From the second until the fifth postoperative day (POD), CRP levels were significantly higher (p = 0.023, p < 0.001, p = 0.002, and p = 0.002, respectively) in these patients. CRP concentrations above 166 mg/L on POD3 (AUC 0.75) and 116 mg/L on POD4 (AUC 0.70) were associated with the highest risk of an SAE ≥ 3. Postoperative WBC levels were not significantly different between patients with SAE < 3 and SAE ≥ 3 complications.
CONCLUSION: Data from our hospital suggest that CRP levels that continue to rise after POD2 or that are ≥ 166 mg/L at POD3 or ≥ 116 mg/L at POD4, indicate a considerable risk for developing high-grade SAEs. The cut-off values we found can potentially be used as a threshold for additional diagnostic interventions, after they have been validated in external data.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32524458      PMCID: PMC7752888          DOI: 10.1245/s10434-020-08619-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  32 in total

1.  Anastomotic leakage after lower gastrointestinal anastomosis: men are at a higher risk.

Authors:  Magdalena A Lipska; Ian P Bissett; Bryan R Parry; Arend E H Merrie
Journal:  ANZ J Surg       Date:  2006-07       Impact factor: 1.872

2.  Incidence of leukopenia after intraperitoneal vs combined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei.

Authors:  Philipp Horvath; Stefan Beckert; Florian Struller; Alfred Königsrainer; Ingmar Königsrainer
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

3.  Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients.

Authors:  Olivier Glehen; François N Gilly; Florent Boutitie; Jean M Bereder; François Quenet; Lucas Sideris; Baudouin Mansvelt; Gérard Lorimier; Simon Msika; Dominique Elias
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

4.  Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Terence C Chua; Brendan J Moran; Paul H Sugarbaker; Edward A Levine; Olivier Glehen; François N Gilly; Dario Baratti; Marcello Deraco; Dominique Elias; Armando Sardi; Winston Liauw; Tristan D Yan; Pedro Barrios; Alberto Gómez Portilla; Ignace H J T de Hingh; Wim P Ceelen; Joerg O Pelz; Pompiliu Piso; Santiago González-Moreno; Kurt Van Der Speeten; David L Morris
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

5.  Age-Related Morbidity and Mortality with Cytoreductive Surgery.

Authors:  Madalyn G Peters; Edmund K Bartlett; Robert E Roses; Rachel R Kelz; Douglas L Fraker; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2015-05-27       Impact factor: 5.344

Review 6.  Integrated approach to colorectal anastomotic leakage: Communication, infection and healing disturbances.

Authors:  Cloë L Sparreboom; Zhou-Qiao Wu; Jia-Fu Ji; Johan F Lange
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 7.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

8.  Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.

Authors:  Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos
Journal:  J Am Coll Surg       Date:  2013-12-21       Impact factor: 6.113

Review 9.  Diagnostic value of C-reactive protein to rule out infectious complications after major abdominal surgery: a systematic review and meta-analysis.

Authors:  Sarah L Gans; Jasper J Atema; Susan van Dieren; Bas Groot Koerkamp; Marja A Boermeester
Journal:  Int J Colorectal Dis       Date:  2015-05-03       Impact factor: 2.571

10.  Prognostic Factors Influencing Infectious Complications after Cytoreductive Surgery and HIPEC: Results from a Tertiary Referral Center.

Authors:  Maurizio Cardi; Simone Sibio; Francesco Di Marzo; Francesco Lefoche; Claudia d'Agostino; Giovanni Battista Fonsi; Giuseppe La Torre; Ludovica Carbonari; Paolo Sammartino
Journal:  Gastroenterol Res Pract       Date:  2019-05-02       Impact factor: 2.260

View more
  3 in total

1.  Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus.

Authors:  Ruby M van Stein; Christianne A R Lok; Arend G J Aalbers; Ignace H J T de Hingh; Aletta P I Houwink; Herman J Stoevelaar; Gabe S Sonke; Willemien J van Driel
Journal:  Gynecol Oncol Rep       Date:  2022-02-26

2.  The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Michelle V Dietz; Job P van Kooten; Jeroen L A van Vugt; Alexandra R M Brandt-Kerkhof; Cornelis Verhoef; Eva V E Madsen
Journal:  Ann Surg Oncol       Date:  2022-06-01       Impact factor: 4.339

3.  Effect of Preoperative Immunonutrition on Postoperative Major Morbidity after Cytoreductive Surgery and HIPEC in Patients with Peritoneal Metastasis.

Authors:  Alba Fernández-Candela; Alicia Calero; Luís Sánchez-Guillén; Javier Escrig-Sos; José A Barreras; Francisco López-Rodríguez-Arias; Laura Armañanzas; Ana Murcia; Antonio Arroyo; Francisco Javier Lacueva
Journal:  Nutrients       Date:  2021-06-23       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.